April 3 next meeting of the Transparency Council.
The agenda includes:
Preparation of positions on drug evaluation:
Aspaveli (pegcetacoplan) under the drug program "Treatment of patients with nocturnal paroxysmal hemoglobinuria (PNH) (ICD-10 D59.5)."
Tecentriq (atezolizumab) under the drug program "Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)."
Preparation of an opinion on:
The rationale for amending the description of drug program B.122 "Preventive treatment of patients with recurrent attacks of severe hereditary angioedema (ICD-10: D 84.1)",
The possibility...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
